Zealand Pharma A/S (Zealand Pharma A/S) Other Long-Term Liabilities : $14.44 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Other Long-Term Liabilities?

Zealand Pharma A/S's other long-term liabilities for the quarter that ended in Mar. 2024 was $14.44 Mil.

Zealand Pharma A/S's quarterly other long-term liabilities increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($14.44 Mil).

Zealand Pharma A/S's annual other long-term liabilities increased from Dec. 2021 ($2.80 Mil) to Dec. 2022 ($14.19 Mil) but then declined from Dec. 2022 ($14.19 Mil) to Dec. 2023 ($0.00 Mil).

Zealand Pharma A/S Other Long-Term Liabilities Historical Data

The historical data trend for Zealand Pharma A/S's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Other Long-Term Liabilities Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Zealand Pharma A/S Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Zealand Pharma A/S Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.